Biodexa Pharmaceuticals PLC (BDRX)

NASDAQ: BDRX · IEX Real-Time Price · USD
0.496
+0.026 (5.46%)
At close: Mar 28, 2023, 4:00 PM
0.632
+0.136 (27.48%)
Pre-market: Mar 29, 2023, 5:12 AM EDT
5.46%
Market Cap 1.98M
Revenue (ttm) 570,732
Net Income (ttm) -3.73M
Shares Out 4.92M
EPS (ttm) -3.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 30,523,682
Open 0.694
Previous Close 0.470
Day's Range 0.400 - 0.825
52-Week Range 0.400 - 21.000
Beta 1.22
Analysts n/a
Price Target n/a
Earnings Date Apr 25, 2023

About BDRX

Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTD219, a long-actin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 20
Stock Exchange NASDAQ
Ticker Symbol BDRX
Full Company Profile

Financial Performance

In 2021, BDRX's revenue was 578,000, an increase of 68.51% compared to the previous year's 343,000. Losses were -5.46 million, -75.39% less than in 2020.

Financial numbers in GBP Financial Statements

News

Why Is Midatech Pharma (BDRX) Stock Up 64% Today?

Midatech Pharma (NASDAQ: BDRX) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program. According to a filing with the Securities and Exchange Commissio...

20 hours ago - InvestorPlace

Midatech Pharma PLC Announces R&D Programme Focused on Leptomeningeal Disease

ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 27, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of med...

1 day ago - Accesswire

Midatech Pharma PLC Announces Results of General Meeting

Share Consolidation, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIM ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 24, 2023 / Midatech Pharma PLC (AIM:MTPH)(Nasda...

4 days ago - Accesswire

Midatech Pharma PLC Announces Further re: Notice of General Meeting

ABINGDON, OXFORDSHIRE / ACCESSWIRE / March 10, 2023 / Further to the announcement made on 8 March 2023 providing notice of a general meeting (the "GM") of the Company to be held on 24 March 2023, and ...

2 weeks ago - Accesswire

Midatech Pharma PLC Announces Posting of Circular and Notice of General Meeting

Proposed Share Consolidation, Authority to Allot Shares, Disapplication of Pre-Emption Rights, Change of Name, Adoption of New Articles and Cancellation of Admission to Trading on AIM ABINGDON, OXFORD...

3 weeks ago - Accesswire

Midatech Pharma PLC Announces Closing of $6.0m Private Placement & Broker Change

ABINGDON, UK / ACCESSWIRE / February 15, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines...

1 month ago - Accesswire

Midatech Pharma PLC Announces Private Placement Raising US $6.0 million

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (THE "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CA...

1 month ago - Accesswire

Midatech Pharma PLC Announces Receipt of NASDAQ Notice

ABINGDON, OXFORDSHIRE / ACCESSWIRE / February 3, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of me...

1 month ago - Accesswire

Midatech Pharma PLC Announces Result of General Meeting

Result of General Meeting Appointment of Specialist Business Advisory Firm - Quantuma ABINGDON, OXFORDSHIRE / ACCESSWIRE / January 23, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug deliv...

2 months ago - Accesswire

Midatech Pharma PLC Announces Planned Dose Escalation in MTX-110 Phase 1 Study

Planned Dose Escalation in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma ABINGDON, UK / ACCESSWIRE / January 12, 2023 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP)...

2 months ago - Accesswire

Midatech Pharma PLC Announces Closing of Offering, Revised Terms, AIM & Webinar

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFE...

3 months ago - Accesswire

Midatech Pharma PLC Announces Proposed Acquisition of Bioasis Technologies Inc

NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO CANADA, AUSTRALIA, JAPAN OR THE REPUBLIC OF SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH OFFE...

3 months ago - Accesswire

Midatech Pharma PLC - First Patient Enrolled in Phase 1 Study of MTX-110

First Patient Enrolled in Phase 1 Study of MTX-110 (MAGIC-G1 Study) in Patients with Recurrent Glioblastoma ABINGDON, OXFORDSHIRE / ACCESSWIRE / November 14, 2022 / Midatech Pharma PLC (AIM:MTPH.L; Na...

4 months ago - Accesswire

Midatech Pharma PLC Announces Receipt of NASDAQ Notification

ABINGDON, OXFORDSHIRE / ACCESSWIRE / October 18, 2022 / Midatech Pharma (AIM:MTPH)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, ann...

5 months ago - Accesswire

Midatech Pharma PLC Announces ADR Ratio Change

ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 14, 2022 / Midatech Pharma (AIM:MTPH)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, a...

6 months ago - Accesswire

Midatech Pharma PLC Announces Interim Results for the Six Months to 30 June 2022

ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 14, 2022 / Midatech Pharma Plc (AIM:MTPH; NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of me...

7 months ago - Accesswire

Midatech Pharma PLC Announces MTX110 Development for the Treatment of Glioma

Orphan Designation Granted by EMA to MTX110 Development for the Treatment of Glioma ABINGDON, NR / ACCESSWIRE / June 21, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology compa...

10 months ago - Accesswire

Midatech Pharma PLC Announces Directorate Change

ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 20, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, ...

10 months ago - Accesswire

Midatech Pharma PLC - MTX110 Study to be Presented at ISPNO 2022

ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 10, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, ...

10 months ago - Accesswire

Midatech Pharma PLC Announces Retirement of Chairman and Proposed New Chairman

ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 10, 2022 / Midatech Pharma PLC (AIM:MTPH.L)(Nasdaq:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, ...

10 months ago - Accesswire

Midatech Pharma's Shares Shoot Higher On FDA Fast Track Designation For Malignant Brain Tumor Drug

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Midatech Pharma PLC's (NASDAQ: MTP) lead drug candidate MTX110 for the treatment of patients with recurrent glioblasto...

10 months ago - Benzinga

Midatech's investigational glioblastoma treatment gets Fast Track status

U.S.-listed shares of Midatech Pharma PLC ADR MTP, +0.03% MTPH, soared 35.7% in premarket trading on Wednesday after the company said the Food and Drug Administration granted Fast Track status to the ...

10 months ago - Market Watch

Midatech Pharma PLC Announces Fast Track Designation for MTX110 Development

Fast Track Designation Granted to MTX110 Development for the Treatment of Recurrent Glioblastoma ABINGDON, OXFORDSHIRE / ACCESSWIRE / June 1, 2022 / Midatech Pharma PLC (AIM:MTPH.L); (NASDAQ:MTP), an ...

10 months ago - Accesswire

Midatech Pharma PLC Announces Posting of Annual Report & Notice of AGM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 24, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicin...

11 months ago - Accesswire

Midatech Pharma PLC Announces Results for the Year Ended 31 December 2021

ABINGDON, OXFORDSHIRE / ACCESSWIRE / April 26, 2022 / Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, an...

1 year ago - Accesswire